Manufactured Object – Page 2

OpenAI launches ChatGPT Health as a dedicated, privacy-focused health assistant

2 weeks ago talkbio0Tagged Apple Health, b.well partnership, ChatGPT Health, DNA Integration, Health care facility, health data privacy, HealthBench, Healthcare AI, Medical Records, wellness apps * *

OpenAI; ChatGPT Health; healthcare AI; medical records integration; Apple Health; wellness apps; health data privacy; HealthBench; b.well partnership; AI in healthcare

Zaka VC Invests in DeepSeq.AI to Transform AI-Based Protein Drug Discovery

2 weeks ago talkbio0Tagged AI-based drug discovery, DARPA-funded initiative * *, datasets, DeepSeq, hyperscaled data, Illumina Ventures, Investments, LLM-based technology, prepulse inhibition activity, protein drug discovery, Vital capacity, Zaka

Zaka VC; DeepSeq.AI; protein drug discovery; AI-based drug discovery; hyperscaled data; LLM-based technology; biotech investment; DARPA-funded initiative; Illumina Ventures; PPI datasets

Corsera Health Launches with $50M Funding for Preventive Cardiovascular RNAi Program Advancing to Clinic

2 weeks ago talkbio0Tagged Ambulatory Care Facilities, Cardiovascular Diseases, Corsera Health, Funding, Preventive Health Programs, RNAi medicine, trials

Corsera Health; cardiovascular disease; RNAi medicine; preventive program; clinic trials; funding; $50M

Quantori and Expert Systems Partner to Accelerate Drug Discovery with Foundational Predictive AI Models

1 month ago talkbio0Tagged AI models, Dosage Forms, Drug Discovery, Expert Systems, Q-Scientist, Quantori, R&D

Quantori; Expert Systems; drug discovery; AI models; Q-Scientist; pharmaceutical R&D

Exclusive: Compounding giant Empower Pharmacy cuts hundreds of staff, stops New Jersey operations

1 month ago talkbio0Tagged compounding pharmacy, East Windsor facility, Empower Pharmacy, Facility (object), Glucagon-Like Peptide 1, Inspection (procedure), layoffs, manufacturing shutdown, New Jersey operations, Outsourcing, Qualitative form, United States Food and Drug Administration, Workforce reduction

Empower Pharmacy; compounding pharmacy; layoffs; job cuts; New Jersey operations; East Windsor facility; manufacturing shutdown; outsourcing facility; FDA inspection; Form 483; compounded GLP-1 drugs; workforce reduction

Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites

1 month ago talkbio0Tagged 2025, Acquisition, Acquisitions, fibroblast growth factor 21, Health care facility, Johnson & Johnson Intra-Cellular, M&A, MASH, Merck Verona, Patent Cliff, Pharma, pharma patent expirations, Sanofi Blueprint Medicines

pharma M&A 2025; biotech acquisitions; patent cliff; pharma patent expirations; Novo Nordisk Akero deal; Johnson & Johnson Intra-Cellular acquisition; Merck Verona Pharma deal; Sanofi Blueprint Medicines acquisition; FGF21 MASH deals; 2025 healthcare deals

RTW-backed startup Yarrow Bioscience signs autoimmune antibody deal with China’s GenSci

1 month ago talkbio0Tagged anti-TSHR antibody, Antibodies, Autoimmune, Changchun GeneScience Pharmaceutical, China, GenSci, GS-098, Investments, RTW, strategic partnership, Thyroid associated opthalmopathies, Yarrow Bioscience, YB-101

RTW Investments; Yarrow Bioscience; GenSci; Changchun GeneScience Pharmaceutical; autoimmune; antibody; GS-098; YB-101; anti-TSHR antibody; thyroid eye disease; China; ex-China rights; strategic partnership; licensing deal

FDA broadens label for Amgen’s Uplizna as it enters rare disease competition

1 month ago talkbio0Tagged AChR-positive, amgen, Approved, disease market, dosing, expansion, gMG, IgG4-Related Disease, inebilizumab, Infrequent, Labels (device), MINT trial, MuSK-positive, Myasthenia Gravis, Generalized, Neuromyelitis Optica, twice-yearly, United States Food and Drug Administration, Uplizna

Uplizna; inebilizumab; Amgen; FDA approval; label expansion; generalized myasthenia gravis; gMG; AChR-positive; MuSK-positive; neuromyelitis optica spectrum disorder; NMOSD; IgG4-related disease; rare disease market; MINT trial; twice-yearly dosing

The Endpoints 100: Biotech CEOs are feeling more upbeat about the road ahead

1 month ago talkbio0Tagged Attitude, biopharma executives, CEOs, dealmaking, E100 survey, Endpoints, Industry, IPO, Market, Recovery - action, reorganization, Sentiment, Trump administration, United States Food and Drug Administration, Window (physical object)

Endpoints 100; E100 survey; biotech CEOs; biopharma executives; industry sentiment; market recovery; dealmaking; IPO window; Trump administration; FDA reorganization; tariffs; 2025 outlook

Health tech investors are getting creative with exits in 2025

1 month ago talkbio0Tagged 2025, AI healthtech IPOs, Exit, healthtech, Investments, M&A consolidation, Private Equity, provider operations, roll-ups, secondary markets, trends qualifier, Vital capacity

healthtech exits 2025; creative exit strategies; M&A consolidation; secondary markets; private equity roll-ups; AI healthtech IPOs; provider operations investment; VC healthtech trends